Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.

Anamarija Pfeiffer Giulia Franciosa Marie Locard-Paulet Ilaria Piga Kristian ReckzehVidyasiri VemulapalliStephen C Blacklow Kim Theilgaard-Mönch Lars Juhl Jensen Jesper Velgaard Olsen

Published in: Cancer research (2022)

These findings suggest that combined inhibition of SHP2 and FLT3 effectively treat FLT3-ITD-positive AML, highlighting the need for development of more potent SHP2 inhibitors and combination therapies for clinical applications.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
small molecule
tyrosine kinase
protein kinase